-
-
-
-
-
-
-
Scilex Holding Company, a Sorrento Company, Announces That the FDA Has Granted Fast Track Designation for SP-103 (Lidocaine Topical System) 5.4%, Next Generation Triple Strength Formulation of ZTlido�
-
-
-
-
-
-
-
Scilex Holding Company, a Sorrento Company, enters into an agreement for an exclusive license with ROMEG Therapeutics, LLC, for the right to commercialize Gloperba®, an FDA-approved prophylactic trea
-
-
-
-
-
-
-
Scilex Holding Company, a Sorrento Company, and Vickers Vantage Corp. I announced today the filing of a Registration Statement on Form S-4 with the Securities and Exchange Commission relating to the p
-
-
-
-
-
-
-
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Announces Expanding Its Direct Distribution Network to National And Regional Wholesalers And Pharmacies
-
-
-
-
-
-
-
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., enters into a Non-Binding Term Sheet for a $5 Billion Committed Equity Financing Facility to be Effective in Connect
-
-
-
-
-
-
-
Scilex Holding Company, a Sorrento Therapeutics, Inc. Subsidiary, Announces Highly Significant Positive Top-Line Results from its Phase 3 Non-Opioid Injectable SP-102 (SEMDEXA™) Pivotal Trial C.L.E.
-
-
-
-
27,721 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

